Phosphodiesterase Inhibitors

• 

  Subject Areas on Research

  • A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. 
  • Ablation of calcineurin Aβ reveals hyperlipidemia and signaling cross-talks with phosphodiesterases. 
  • Acute dysphonia secondary to vocal fold hemorrhage after vardenafil use. 
  • Adenylyl cyclase expression and modulation of cAMP in rat taste cells. 
  • Antimitotic and cytotoxic effects of theophylline in MDA-MB-231 human breast cancer cells. 
  • Chronic obstructive pulmonary disease: emerging medical therapies. 
  • Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei. 
  • Compartmentalization of cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation of vasopressin-mediated water reabsorption in renal principal cells. 
  • Cyclic GMP is a second messenger by which nitric oxide inhibits diaphragm contraction. 
  • Erectile function after posterior urethroplasty for pelvic fracture-urethral distraction defect injuries. 
  • Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. 
  • Generation of reactive oxygen species by xanthine derivatives in MDA-MB-231 human breast cancer cells. 
  • Host-Directed Therapies for Tuberculosis. 
  • Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. 
  • Inositol pyrophosphates modulate S phase progression after pheromone-induced arrest in Saccharomyces cerevisiae. 
  • Intravenous milrinone in cardiac surgery. 
  • Isolation and characterization of a protein from rat testis which inhibits cyclic AMP-dependent protein kinase and phosdiesterase. 
  • Luteinizing hormone (LH) drives diverse intracellular calcium second messenger signals in isolated porcine ovarian thecal cells: preferential recruitment of intracellular Ca2+ oscillatory cells by higher concentrations of LH. 
  • Mapping of effector binding sites of transducin alpha-subunit using G alpha t/G alpha i1 chimeras. 
  • Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. 
  • New cardiac drugs. 
  • New concepts in the treatment of anaphylactoid reactions in anesthesia. 
  • Newer pharmacologic alternatives for erectile dysfunction. 
  • PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support. 
  • Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. 
  • Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. 
  • Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. 
  • Phosphodiesterase inhibitors: the inotropes of choice for the new millennium? 
  • Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen. 
  • Photoreceptor phosphodiesterase: interaction of inhibitory gamma subunit and cyclic GMP with specific binding sites on catalytic subunits. 
  • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. 
  • Preincisional intravenous pentoxifylline attenuating perioperative cytokine response, reducing morphine consumption, and improving recovery of bowel function in patients undergoing colorectal cancer surgery. 
  • Prevention of chronic cerebral vasospasm in dogs with milrinone. 
  • Protein phosphatases mediate depotentiation induced by high-intensity theta-burst stimulation. 
  • Protein synthesis-dependent potentiation by thyroxine of antiviral activity of interferon-gamma. 
  • Randomized controlled trial investigating the effect of transcervical papaverine and bupivacaine on postoperative analgesia following laparoscopic sterilization. 
  • Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. 
  • Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. 
  • Receptor-induced transient reduction in plasma membrane PtdIns(4,5)P2 concentration monitored in living cells. 
  • Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. 
  • Regulation of insulin secretion from novel engineered insulinoma cell lines. 
  • Retinal effects of 6 months of daily use of tadalafil or sildenafil. 
  • Sexual dysfunction in men and women with endocrine disorders. 
  • Sildenafil improves walk distance in idiopathic pulmonary fibrosis. 
  • Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options. 
  • The effects of milrinone on platelets in patients undergoing cardiac surgery. 
  • The in vitro effects of phosphodiesterase inhibitors on the human internal mammary artery. 
  • Tumor necrosis factor increases mitochondrial oxidant production and induces expression of uncoupling protein-2 in the regenerating mice [correction of rat] liver. 
  • Ultrasound-mediated release of hydrophilic and lipophilic agents from echogenic liposomes. 
  • beta-Arrestin: a protein that regulates beta-adrenergic receptor function. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology